# A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

> **NCT06144385** · PHASE1 · UNKNOWN · sponsor: **Shanghai Ming Ju Biotechnology Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Liver Carcinoma
- Hepatic Cell Carcinoma

## Interventions

- **BIOLOGICAL:** CAR-GPC3 T cells

## Key facts

- **NCT ID:** NCT06144385
- **Lead sponsor:** Shanghai Ming Ju Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-24
- **Primary completion:** 2024-03
- **Final completion:** 2024-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06144385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06144385, "A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06144385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*